Efficacy of pembrolizumab monotherapy for advanced gingival malignant melanoma: A case report

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology Pub Date : 2025-03-22 DOI:10.1016/j.oraloncology.2025.107267

Jie Li , Chong-tao Xu , Wei Wu

引用次数: 0

Abstract

Oral malignant melanoma specifically denotes a rare subtype of melanoma originating in oral mucosa, characterized by a generally poor prognosis. Inhibitors targeting programmed cell death protein-1 or its ligand-1 (PD-1/PD-L1) have become widely accepted as primary treatments for malignant melanoma. The current report describes a unique case of advanced gingival malignant melanoma treated with pembrolizumab monotherapy in a 67-year-old Asian female. The report comprehensively evaluates the therapeutic potential of pembrolizumab, as well as its immune-related adverse events (irAEs).

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Oral oncology 医学-牙科与口腔外科

CiteScore

8.70

自引率

10.40%

发文量

505

审稿时长

20 days

期刊介绍： Oral Oncology is an international interdisciplinary journal which publishes high quality original research, clinical trials and review articles, editorials, and commentaries relating to the etiopathogenesis, epidemiology, prevention, clinical features, diagnosis, treatment and management of patients with neoplasms in the head and neck. Oral Oncology is of interest to head and neck surgeons, radiation and medical oncologists, maxillo-facial surgeons, oto-rhino-laryngologists, plastic surgeons, pathologists, scientists, oral medical specialists, special care dentists, dental care professionals, general dental practitioners, public health physicians, palliative care physicians, nurses, radiologists, radiographers, dieticians, occupational therapists, speech and language therapists, nutritionists, clinical and health psychologists and counselors, professionals in end of life care, as well as others interested in these fields.